|
1
|
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.
|
Lancet Oncol
|
2009
|
12.41
|
|
2
|
Revised international prognostic scoring system for myelodysplastic syndromes.
|
Blood
|
2012
|
8.12
|
|
3
|
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.
|
N Engl J Med
|
2004
|
7.73
|
|
4
|
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.
|
J Clin Oncol
|
2009
|
6.54
|
|
5
|
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
|
Lancet Oncol
|
2010
|
4.67
|
|
6
|
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
|
Cancer
|
2008
|
3.75
|
|
7
|
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
|
Blood
|
2011
|
3.28
|
|
8
|
Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice.
|
Exp Hematol
|
2004
|
2.81
|
|
9
|
Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation.
|
J Clin Oncol
|
2008
|
2.74
|
|
10
|
Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts.
|
Haematologica
|
2008
|
2.69
|
|
11
|
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model.
|
Haematologica
|
2008
|
2.32
|
|
12
|
Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
|
Biol Blood Marrow Transplant
|
2006
|
1.53
|
|
13
|
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
|
Cancer
|
2011
|
1.51
|
|
14
|
Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
|
Br J Haematol
|
2007
|
1.39
|
|
15
|
Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
|
Blood
|
2013
|
1.32
|
|
16
|
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
|
Haematologica
|
2012
|
1.28
|
|
17
|
Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
|
Clin Cancer Res
|
2005
|
1.27
|
|
18
|
Unrelated cord blood transplants in adults with hematologic malignancies.
|
Haematologica
|
2006
|
1.27
|
|
19
|
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.
|
Ann Hematol
|
2008
|
1.20
|
|
20
|
Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.15
|
|
21
|
Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
|
Leuk Res
|
2010
|
1.02
|
|
22
|
Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
|
J Clin Oncol
|
2013
|
0.97
|
|
23
|
Donor CTLA-4 genotype influences clinical outcome after T cell-depleted allogeneic hematopoietic stem cell transplantation from HLA-identical sibling donors.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
24
|
Umbilical cord blood transplantation.
|
Curr Opin Hematol
|
2004
|
0.94
|
|
25
|
Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.
|
Br J Haematol
|
2014
|
0.86
|
|
26
|
Unrelated transplantation for poor-prognosis adult acute lymphoblastic leukemia: long-term outcome analysis and study of the impact of hematopoietic graft source.
|
Biol Blood Marrow Transplant
|
2010
|
0.85
|
|
27
|
Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.
|
Genes Chromosomes Cancer
|
2013
|
0.83
|
|
28
|
Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes.
|
Leuk Lymphoma
|
2013
|
0.83
|
|
29
|
Hla-DPB1 mismatch in HLA-A-B-DRB1 identical sibling donor stem cell transplantation and acute graft-versus-host disease.
|
Transplantation
|
2004
|
0.82
|
|
30
|
FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
|
Leuk Res
|
2002
|
0.82
|
|
31
|
Characteristics of and risk factors for pneumonia in patients with hematological malignancies developing fever after autologous blood stem cell transplantation.
|
Leuk Lymphoma
|
2007
|
0.81
|
|
32
|
Iron overload and chelation therapy in patients with low-risk myelodysplastic syndromes with transfusion requirements.
|
Ann Hematol
|
2009
|
0.80
|
|
33
|
CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
|
Clin Cancer Res
|
2004
|
0.80
|
|
34
|
Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
|
Ann Hematol
|
2014
|
0.79
|
|
35
|
A study of incidence and characteristics of infections in 476 patients from a single center undergoing autologous blood stem cell transplantation.
|
Int J Hematol
|
2007
|
0.78
|
|
36
|
Umbilical cord blood transplantation from unrelated donors in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Haematologica
|
2013
|
0.78
|
|
37
|
Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.
|
Leuk Res
|
2013
|
0.77
|
|
38
|
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
|
Eur J Haematol
|
2014
|
0.77
|
|
39
|
Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
40
|
A broken cord blood bag: placing the unit in a sterile zip-lock bag before thawing prevents catastrophic events.
|
Transfusion
|
2008
|
0.75
|